<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Incanthera Plc — News on 6ix</title>
    <link>https://6ix.com/company/incanthera-plc</link>
    <description>Latest news and press releases for Incanthera Plc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 31 Mar 2026 06:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/incanthera-plc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d5816ebeedb30cb6f8a7eb.webp</url>
      <title>Incanthera Plc</title>
      <link>https://6ix.com/company/incanthera-plc</link>
    </image>
    <item>
      <title>Commercial Update</title>
      <link>https://6ix.com/company/incanthera-plc/news/commercial-update-13</link>
      <guid isPermaLink="true">https://6ix.com/company/incanthera-plc/news/commercial-update-13</guid>
      <pubDate>Tue, 31 Mar 2026 06:00:00 GMT</pubDate>
      <description>Incanthera plc reported disappointing direct-to-consumer sales for its Skin+CELL product in the first quarter of 2026, generating only £12,400 from 177 units sold, significantly below initial expectations. While the company is working to refresh its DTC website and marketing, it is actively pursuing bulk sales discussions with three interested parties in Europe, Asia, and the Middle East, though no agreements have been finalized. Additionally, Incanthera is exploring technology licensing opportu</description>
    </item>
    <item>
      <title>Half-year Report</title>
      <link>https://6ix.com/company/incanthera-plc/news/half-year-report-774</link>
      <guid isPermaLink="true">https://6ix.com/company/incanthera-plc/news/half-year-report-774</guid>
      <pubDate>Thu, 11 Dec 2025 07:20:00 GMT</pubDate>
      <description>Incanthera plc reported its interim results for the six months ended 30 September 2025, highlighting the global launch of its Skin+CELL skincare range via a dedicated Direct To Consumer website, which has shown steady month-on-month increases in traction and sales conversion. The company incurred an operating loss of £888,000 for the period, compared to £695,000 in the prior year, with basic and diluted loss per share at (0.69) pence. Cash and cash equivalents stood at £215,000 as of 30 Septembe</description>
    </item>
    <item>
      <title>Aquis Showcase Investor Presentation</title>
      <link>https://6ix.com/company/incanthera-plc/news/aquis-showcase-investor-presentation</link>
      <guid isPermaLink="true">https://6ix.com/company/incanthera-plc/news/aquis-showcase-investor-presentation</guid>
      <pubDate>Mon, 17 Nov 2025 07:00:00 GMT</pubDate>
      <description>Incanthera plc, a company focused on dermatology and oncology technologies, will be presenting and exhibiting at the fourth Aquis Showcase conference on November 19, 2025, at the Royal College of Surgeons in London. The company&apos;s Chairman and CEO will introduce Incanthera to delegates, and a copy of the presentation will be available on the company&apos;s website.
                Disclaimer*</description>
    </item>
    <item>
      <title>AGM 2025 Presentation Materials</title>
      <link>https://6ix.com/company/incanthera-plc/news/agm-2025-presentation-materials</link>
      <guid isPermaLink="true">https://6ix.com/company/incanthera-plc/news/agm-2025-presentation-materials</guid>
      <pubDate>Mon, 10 Nov 2025 11:04:00 GMT</pubDate>
      <description>Incanthera plc has announced that materials from its Annual General Meeting held on November 7, 2025, including a recording and presentation, are now available on the company&apos;s website. The company, which focuses on innovative technologies in dermatology and oncology, also highlighted its Skin + CELL luxury skincare brand, launched in August 2025, which utilizes advanced formulation and delivery expertise.
                Disclaimer*</description>
    </item>
    <item>
      <title>Result of AGM</title>
      <link>https://6ix.com/company/incanthera-plc/news/result-of-agm-1181</link>
      <guid isPermaLink="true">https://6ix.com/company/incanthera-plc/news/result-of-agm-1181</guid>
      <pubDate>Fri, 07 Nov 2025 14:30:00 GMT</pubDate>
      <description>Incanthera plc announced that all resolutions were duly passed at its Annual General Meeting held on 7 November 2025. While resolutions for re-electing a director, appointing auditors, authorizing share allotments, and disapplying pre-emption rights passed with overwhelming majorities, Resolution 1, concerning the company&apos;s annual reports and accounts for the financial year ended 31 March 2025, saw 13,065,834 votes, or 26.83%, cast against it. This resolution
                Disclaimer*</description>
    </item>
    <item>
      <title>AGM 2025 Update</title>
      <link>https://6ix.com/company/incanthera-plc/news/agm-2025-update</link>
      <guid isPermaLink="true">https://6ix.com/company/incanthera-plc/news/agm-2025-update</guid>
      <pubDate>Thu, 06 Nov 2025 07:00:00 GMT</pubDate>
      <description>AGM 2025 Update.</description>
    </item>
    <item>
      <title>Proactive Investor Forum Presentation</title>
      <link>https://6ix.com/company/incanthera-plc/news/proactive-investor-forum-presentation</link>
      <guid isPermaLink="true">https://6ix.com/company/incanthera-plc/news/proactive-investor-forum-presentation</guid>
      <pubDate>Thu, 16 Oct 2025 09:15:00 GMT</pubDate>
      <description>Incanthera plc announced that the recording of their presentation at the Proactive Investor Forum in London on October 9, 2025, is now available for viewing. The presentation recording can be accessed via a provided YouTube link. Additionally, the investor presentation given that evening is available on the company&apos;s website. This information is considered non-regulatory.

                Disclaimer*</description>
    </item>
    <item>
      <title>Notice of AGM</title>
      <link>https://6ix.com/company/incanthera-plc/news/notice-of-agm-646</link>
      <guid isPermaLink="true">https://6ix.com/company/incanthera-plc/news/notice-of-agm-646</guid>
      <pubDate>Tue, 14 Oct 2025 06:00:00 GMT</pubDate>
      <description>Incanthera plc announced the posting of its Annual Report and Accounts for the year ended March 31, 2025, along with the Notice of Annual General Meeting (AGM) and accompanying proxy form, to shareholders and the company website. The AGM will be held on November 7, 2025, at 11:00 am at Gateley Plc in London. Shareholders can follow the proceedings online via the Investor Meet Company platform, but online voting will not be available; proxy votes are requested. Questions for the Board can be pre-</description>
    </item>
    <item>
      <title>Investor Presentation</title>
      <link>https://6ix.com/company/incanthera-plc/news/investor-presentation-642</link>
      <guid isPermaLink="true">https://6ix.com/company/incanthera-plc/news/investor-presentation-642</guid>
      <pubDate>Mon, 06 Oct 2025 06:00:00 GMT</pubDate>
      <description>Incanthera PLC announced that it will present at the Proactive Investor Forum in London on October 9, 2025, at 6:00 p.m. The presentation will be given to high net worth investors, fund managers, private client brokers, and analysts. The presentation will not contain any inside information and will be available on the company&apos;s website at www.incanthera.com. Registration for the event is available through a provided link. The announcement confirms that the information is of a non-regulatory natu</description>
    </item>
    <item>
      <title>Final Results</title>
      <link>https://6ix.com/company/incanthera-plc/news/final-results-758</link>
      <guid isPermaLink="true">https://6ix.com/company/incanthera-plc/news/final-results-758</guid>
      <pubDate>Tue, 30 Sep 2025 07:15:00 GMT</pubDate>
      <description>Incanthera PLC announced its audited results for the year ended March 31, 2025, highlighting the launch of its Skin+CELL luxury skincare range on August 11, 2025, and the achievement of first revenues from the range in its initial weeks. The company completed an institutional fundraise of £508,000 in June 2025. The total group loss for the year before exceptional items was £1,997k, which included a charge for share-based compensation of £214k. Operating expenses excluding share-based compensatio</description>
    </item>
    <item>
      <title>SKIN + CELL COMMERCIAL WEBSITE NOW OPEN FOR SALES</title>
      <link>https://6ix.com/company/incanthera-plc/news/skin-cell-commercial-website-now-open-for-sales</link>
      <guid isPermaLink="true">https://6ix.com/company/incanthera-plc/news/skin-cell-commercial-website-now-open-for-sales</guid>
      <pubDate>Mon, 11 Aug 2025 06:00:00 GMT</pubDate>
      <description>SKIN + CELL COMMERCIAL WEBSITE NOW OPEN FOR SALES.</description>
    </item>
    <item>
      <title>SKIN + CELL TO LAUNCH</title>
      <link>https://6ix.com/company/incanthera-plc/news/skin-cell-to-launch</link>
      <guid isPermaLink="true">https://6ix.com/company/incanthera-plc/news/skin-cell-to-launch</guid>
      <pubDate>Wed, 06 Aug 2025 06:00:00 GMT</pubDate>
      <description>SKIN + CELL TO LAUNCH.</description>
    </item>
    <item>
      <title>Holding(s) in Company</title>
      <link>https://6ix.com/company/incanthera-plc/news/holdings-in-company-1264</link>
      <guid isPermaLink="true">https://6ix.com/company/incanthera-plc/news/holdings-in-company-1264</guid>
      <pubDate>Wed, 09 Jul 2025 06:00:00 GMT</pubDate>
      <description>Holding(s) in Company.</description>
    </item>
    <item>
      <title>Subscription, Directors&apos; Dealing and RPT</title>
      <link>https://6ix.com/company/incanthera-plc/news/subscription-directors-dealing-and-rpt</link>
      <guid isPermaLink="true">https://6ix.com/company/incanthera-plc/news/subscription-directors-dealing-and-rpt</guid>
      <pubDate>Mon, 30 Jun 2025 06:00:00 GMT</pubDate>
      <description>Subscription, Directors&apos; Dealing and RPT.</description>
    </item>
    <item>
      <title>New Findings on Protective Effects of Skin + CELL</title>
      <link>https://6ix.com/company/incanthera-plc/news/new-findings-on-protective-effects-of-skin-cell</link>
      <guid isPermaLink="true">https://6ix.com/company/incanthera-plc/news/new-findings-on-protective-effects-of-skin-cell</guid>
      <pubDate>Wed, 18 Jun 2025 06:00:00 GMT</pubDate>
      <description>New Findings on Protective Effects of Skin + CELL.</description>
    </item>
    <item>
      <title>Direct To Customer Agency Agreement Completed</title>
      <link>https://6ix.com/company/incanthera-plc/news/direct-to-customer-agency-agreement-completed</link>
      <guid isPermaLink="true">https://6ix.com/company/incanthera-plc/news/direct-to-customer-agency-agreement-completed</guid>
      <pubDate>Mon, 02 Jun 2025 06:00:00 GMT</pubDate>
      <description>Direct To Customer Agency Agreement Completed.</description>
    </item>
    <item>
      <title>Warrant Extension, Debt Conversion &amp; Equity Issue</title>
      <link>https://6ix.com/company/incanthera-plc/news/warrant-extension-debt-conversion-and-equity-issue-1</link>
      <guid isPermaLink="true">https://6ix.com/company/incanthera-plc/news/warrant-extension-debt-conversion-and-equity-issue-1</guid>
      <pubDate>Tue, 01 Apr 2025 06:00:00 GMT</pubDate>
      <description>Warrant Extension, Debt Conversion &amp; Equity Issue.</description>
    </item>
    <item>
      <title>Resolution of Allegations of Patent Infringement</title>
      <link>https://6ix.com/company/incanthera-plc/news/resolution-of-allegations-of-patent-infringement</link>
      <guid isPermaLink="true">https://6ix.com/company/incanthera-plc/news/resolution-of-allegations-of-patent-infringement</guid>
      <pubDate>Tue, 25 Mar 2025 15:08:00 GMT</pubDate>
      <description>Resolution of Allegations of Patent Infringement.</description>
    </item>
    <item>
      <title>Further re: Commercial Update</title>
      <link>https://6ix.com/company/incanthera-plc/news/further-re-commercial-update</link>
      <guid isPermaLink="true">https://6ix.com/company/incanthera-plc/news/further-re-commercial-update</guid>
      <pubDate>Tue, 29 Oct 2024 07:00:00 GMT</pubDate>
      <description>Further re: Commercial Update.</description>
    </item>
    <item>
      <title>Extension of Warrants</title>
      <link>https://6ix.com/company/incanthera-plc/news/extension-of-warrants-4</link>
      <guid isPermaLink="true">https://6ix.com/company/incanthera-plc/news/extension-of-warrants-4</guid>
      <pubDate>Mon, 09 Sep 2024 06:01:00 GMT</pubDate>
      <description>Extension of Warrants.</description>
    </item>
  </channel>
</rss>